Prof. Marcio F. Chedid, M.D., Ph.D., Post-Graduate Professor of Surgery, Liver and Pancreas Transplant and Hepatobiliary Surgery Unit, Hospital de Clinicas de Porto Alegre (HCPA-UFRGS), Medical School of UFRGS, Porto Alegre, Brazil Dr. Marcio F. Chedid, M.D., Ph.D., is a Post-Graduate Professor of Surgery at the Medical School of UFRGS and an Attending Surgeon at the Liver and Pancreas Transplant and Hepatobiliary Surgery Unit of HCPA-UFRGS. Dr. Chedid graduated as a Medical Doctor at the Medical School of the Federal University of Rio Grande do Sul (UFRGS) in Porto Alegre, Brazil in 2004. He concluded a five-year General Surgery and Surgical Oncology Residency at Hospital de Clínicas de Porto Alegre (HCPA-UFRGS) in 2010. Dr. Chedid obtained the ECFMG certification and worked as a Clinical Fellow at the Division of Abdominal Transplantation Surgery of Mayo Clinic in Rochester, MN, United States, from 2011 to December 2013. He then attended a Visiting Scholarship at the Department of Surgery of the Washington University in Saint Louis. Dr. Chedid also obtained a Ph.D. degree in Surgical Sciences at UFRGS. Dr. Chedid was the first surgeon to report successful performance of human pancreas transplantation utilizing IGL-1 preservation solution (https://www.ncbi.nlm.nih.gov/pubmed/27163542). Dr. Chedid has authored/co-authored a total of 73 scientific articles. He is the associate editor of the World Journal of Gastrointestinal Surgery, a member of the editorial board of two other indexed journals and has worked as a peer-reviewer for 40 scientific journals, including the American Journal of Transplantation and Transplantation. Peer reviewer for over 50 PubMed indexed journals. Five editorials written Imoprove the field of Liver Transplantation and Gastrointestinal Surgery Saving lives Helping sick patients Prof. Chedid leads the Liver Surgery and Transplant Group of HCPA-UFRGS and his main research interests are investigation on the pre-transplant and early post-transplant markers of acute liver allograft dysfunction and failure following liver transplantation. This research group recently has detected that low Serum Factor V levels on post-transplant day 1 and 2 are associated with post-transplant graft failure and patient death (https://pubmed.ncbi.nlm.nih.gov/30130328/, https://pubmed.ncbi.nlm.nih.gov/25708642/). Another pioneering report of this research group has revealed that pre-transplant ALBI Grade 3 also is associated to negative post-transplant outcomes (https://pubmed.ncbi.nlm.nih.gov/30637547/). - Rock band lead and singer - Sports player - Soccer fan